This study focuses on the innovative mechanism of action of a new molecule, which works on the basis of targeted molecular therapy. The purpose of this study is to evaluate the efficacy and safety of the molecule.
Current treatments for patients with SLE are based primarily on immunosuppressive drugs. Although these treatments can reduce mortality and significantly lengthen patients’ life expectancies, numerous adverse effects may result because these treatments are aggressive and the adverse effects are sometimes worse than the disease itself.
Therefore, more targeted immune suppression therapy is being developed to improve the benefit-risk balance of SLE treatments
This is a phase 3, randomised, double-blind, parallel- group, placebo-controlled clinical study.
Duration : 52 weeks
Men and women between 18 and 70 years of age
Systemic lupus erythematosus
Treated or untreated